



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 24th August, 2020

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 80th meeting held on 26th June, 2020 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP but not later than 13th September, 2020. Replies received after due date shall not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
Millennium Laboratories, Lahore 128/5, Shaikh Mohammad Raiz Road, Quaid-e-Azam, Industrial Estate Road, Kot Lakhpat, Lahore		
1.	Wiser Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Food supplement section availability is required. • Monographs of all ingredients are required. • Information regarding source of carbohydrates, fats, cholesterol and proteins is required. • Testing method of finished product is required.
2.	Xporen Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required. • Testing method of finished product is required.
3.	M-Cal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required. • Justification of 3 tablets as serving dose is required.
4.	Mega Plus tablets	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients including blend are required. • Justification of 2 tablets as serving dose is required. • Testing method of finished product is required.
5.	Key Vit Tablets	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Stability of omega 3 and omega 6 in tablet is required. • Monographs of all ingredients are required.
6.	Inomalt F Tablets	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.

S.No (1)	Brand name (2)	Decision (3)
7.	Geomilk Supplement	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Food supplement section availability is required. • Monographs of all ingredients are required. • Justification is required regarding use of zinc oxide in oral dosage forms. • Testing method of finished product is required.
8.	Ferton Tablets	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.
9.	Ferrosip Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required. • Brand name needs to be changed.
10.	Vox Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
11.	Calgrow Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Brand names differ on form 3 and covering letter, needs clarification. • Monographs of vitamin K2 and red algae calcium are required.
12.	Chemcal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of Co enzyme Q10 is required.
13.	Ecocal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.
14.	Heptolax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Silymarin comes under common molecules list.
15.	Ozcal Flash Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.
16.	Sureway Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of full cream milk and whey milk are required. • Dextrose comes under common molecules list.
17.	Urone K Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Potassium citrate as single ingredient is registered as urinary alkalizing agent, added in common molecules list.
18.	Calpar Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of L methyl folate is required.
19.	Bioloba Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of ginkgo biloba is required.
20.	Cozam Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
21.	Lycoz Tablet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of spirulina extract is required.
22.	MontarVit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.
23.	Geocal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.
24.	Spirovin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of chiro inositol is required. • N acetyl cysteine comes under common molecules list.
25.	Inovit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of ginger extract is required.
26.	Glumin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required. • Chondroitin and glucosamine come under common molecules list.
27.	Irofol Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
28.	Oriseng Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of red ginseng extract is required
29.	Cino Z Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of zinc, vitamin C are required.
30.	Trox Forte Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of tribulus extract, arginine, chlorophytum borivianum, ginseng extract, saffron and epimedium comp extract are required. • Testing method of finished product is required.
31.	Cino D Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Drop filling machine availability is required as firm has liquid(syrup) section only.
32.	Sinum Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
33.	Permit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of vitamin E, iron bisglycinate and zinc is required. • Testing method of finished product is required.
34.	Cartimax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Chondroitin, glucosamine and hyaluronic acid come under common molecules list.
35.	Oral C Tablet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of vitamin K2 is required.
36.	Five C 1000 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of zinc, vitamin C, boron, horsetail extract are required.
37.	Colisan Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Aluminium hydroxide and magnesium hydroxide are registered as drugs, added in common molecules list.
38.	Alfanase Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Drop filling machine availability is required as firm hold liquid (syrup) section only.
39.	Zecop Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of L-ornithine L-aspartate is required. • Fee challan is not endorsed by concerned division of DRAP.
40.	Cofmaxl Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Firm applied herbs in crude form while firm possess nutraceutical facility. • Fee challan is not endorsed by concerned division of DRAP.
41.	Ezine Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Melatonin comes under common molecules list. • Monograph of theanine is required.
42.	Bon D Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of vitamin K2 and red algae calcium are required.
43.	Best Vit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of inositol is required.
44.	Plus D Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of ossien mineral complex is required, added in common molecules list.
45.	Osical Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of ossien mineral complex is required, added in common molecules list.
46.	Plus D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
47.	Cranbest Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of all ingredients are required.
48.	Minimax Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Availability of drop filling machine is required as firm holds liquid (syrup) section only.



S.No (1)	Brand name (2)	Decision (3)
49.	Unimax Supplement Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of iron bisglycinate, cupric chloride, iodine, chromium picolinate, molybdenum and codex alimentarius are required. • Availability of food supplement section is required. • Testing method of finished product is required. • Strength of all ingredients per serving dose is required according to their RDA values.
50.	Minocal D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of chiro-inositol, L methyl folate are required. • Melatonin comes under common molecules list.
51.	Bh Iron Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of iron bisglycinate, copper sulphate and folic acid are required.
52.	D Myth Oral Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Availability of drop filling machine is required.
53.	Famisafe Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of DHA, vitamin E, vitamin K, vitamin B5, biotin, sodium, chloride, calcium carbonate, copper sulphate, iodine and iron bisglycinate are required. • Testing method of finished product is required. • Source of fats, carbs and proteins are required. • Food supplement section availability is required.
54.	Macmin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of folic acid, pantothenic acid and zinc are required. • Fee challan is not endorsed by concerned division of DRAP.
55.	Dg Nex Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Sodium bicarbonate comes under common molecules list. • Firm uses ginger herb in crude form while firm possess nutraceutical facility, needs clarification.
56.	Biokof Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Drop filling machine availability is required as firm holds liquid (syrup) section only.
57.	Bh Iron Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of iron bisglycinate and copper chloride is required.
58.	Infert Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of tribulus, zinc and selenium are required. • Justification is required regarding use of zinc oxide in oral dosage form.
59.	Eco-X Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Aescin comes under common molecules list. • Monograph of colchicum extract is required.
60.	Maxifol Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP.



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Monograph of ginger extract is required.
61.	Biofax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Vinpocetine comes under common molecules list. • Monographs of all ingredients in extract form are required. • Testing method of finished product is required.
62.	Silebro Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Silymarin comes under common molecules list.
63.	Kufset Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Ammonium chloride is registered as drug. • Use of ipecacacuanha extract is required as it also stimulates emesis.
64.	Chemvit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Trypsin and chymotrypsin are proteolytic enzymes, come under common molecules list.
65.	Sinofeb Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Fenofibrate is registered as anti-hyperlipidemic drug.
66.	Ferrofer Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monograph of lipofer is required. • Salt of iron and its monograph is required
67.	Lutex Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of zeaxanthin and lutein are required.
68.	Irobest Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of iron bisglycinate, L methyl folate and copper sulphate are required.
69.	Urosil D Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of cranberry and mannose are required.
70.	Mv Sip Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Salt of calcium and its monograph are required. • Justification is required regarding use of zinc oxide in oral dosage form.
71.	Crantec Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of cranberry extract, calcium phosphate (source of calcium) and calcium phosphate (source of phosphorus) are required.
72.	Probex Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of wheat dextrin fiber is required. • Senoside comes under common molecules list.
73.	Sb-C Tablet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Caffeine is included in common molecules list. • Monograph of guarana seed extract is required. • Testing method of finished of finished product is required.
74.	Alfabex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of cranberry extract and ginger extract are required.
75.	Tribest Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee challan is not endorsed by concerned division of DRAP. • Monographs of zinc, Co enzyme Q 10, lutein, bacopin, taurine, green tea extract, tribulus terrestris extract, macuna extract, withania extract and epimedium saittatum extract are required. • Justification is required regarding use of zinc oxide in oral dosage form. • Testing method of finished product is required.
Oasis Pharma, Lahore		
76.	Apit Rise Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of folium extract is required. • Product resembles with Apetar syrup with minor difference of only one ingredient, needs clarification.
77.	Neokol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of hederae folium extract and adhatoda vasica are required.
78.	Oci Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of red algae (calcium) and iron are required.
79.	MN Zinc Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of zinc gluconate is required.
80.	Ginkar Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of ginkgo biloba extract is required
81.	Ramz Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of zingiber officinale extract, menthe piperata extract, trachspermum ammi and foeniculum vulgare extract are required.
82.	Tresmen Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of horny goat weed extract, maca root extract, togkat ali extract, tribulus terrestris extract are required. • Testing method of finished product is required.
83.	Sovyis Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of hedera helix, morus nigra and adhatoda vasica in extract form are required.
84.	Oecin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of L methyl folate is required.
85.	Ozym-C Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Testing method of finished product is required.
86.	Othin Tablet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Monographs of bacopin, taurin, tribulus terrestris and withania somnifera are required. • Testing method of finished product is required.
87.	Apetar Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Product resembles with apit rise syrup with minor difference of only one ingredient, needs clarification. • Monograph of folium extract is required. • Fee evidence is required.
88.	Osicure Sachet	Deferred for further evaluation and clarification.
89.	Magnovit Powder	Deferred for further evaluation and clarification.
Paragon Herbal Laboratories, Lahore Plot No. Kht 285, Ktn 570, Allah Hoo Industrial Area, Near Sabzi Mandi, Gujumatta, Ferozepur Road, Lahore		
90.	Pe-card syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of vitamin K2 is required.
91.	PE-Nox capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Undertaking of contents of dossiers and brand name are unsigned and un-stamped.
92.	Real cough syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Firm has submitted new proposed brand name i.e multikuff syrup. • Monograph of ivy leaf extract is required.
93.	Revisal tablet	Deferred for following reason(s): <ul style="list-style-type: none"> • Differential fee is required.
94.	Spermodil-F capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of Eurycoma longofolia extract is required. • Brand name needs to be changed.
95.	Stomofil syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is required. • Monograph of calcium lactate gluconate is required.
96.	Vagirena Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Firm has submitted new proposed brand name i.e Fertika tablet. • Monographs of tribulus is required.
97.	V-liver-X syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is required. • Silymarin is added in common molecules list.
98.	V-liver-X tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of milk thistle extract is required. • Brand name needs to be changed.
99.	Colic drops	Deferred for following reasons: <ul style="list-style-type: none"> • Firm has submitted new proposed brand name i.e ADE care drops. • Monographs of all ingredients are required according to BP compendium as mentioned against each ingredient on Form 3.
100.	Gynolec capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of iron bisglycinate and L methyl folate are required. • Firm has submitted new proposed brand name i.e Mediferr Syrup.
101.	Menc on syrup	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Conversion of strength of vitamin D from micro gram to International units is required.
102.	Mency capsule	Deferred for following reasons: <ul style="list-style-type: none"> Stability of omega 3 in hard capsule is required.
103.	Real-Vit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Firm has submitted new proposed brand name i.e Medevit tablet. Monograph of iron bisglycinate is required. Differential fee is required.
104.	Revive Food supplement	Deferred for following reasons: <ul style="list-style-type: none"> Section availability of food supplement alongwith required facilities is required. Monographs of protein, fat, linoleic acid, linolenic acid, DHA, FOS, taurine,carnitine, inositol and codex alimentatious are required. Halal certification of fat and protein is required. Testing method of finished product is required. Unit dose strength is required.
105.	Sharbat Foulad	Deferred for following reasons: <ul style="list-style-type: none"> firm has submitted new proposed brand name i.e Preg-Med tablet. Brand name needs to be changed.
106.	Viron-S Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Firm has submitted new proposed brand name i.e Med-D Insta drop. Firm applied said product in syrupform initially and has changed brand name along with dosage form later, needs clarification.
107.	Cal-Max Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of vitamin K2 is required.
108.	Chew sip Tablet	Deferred for following reasons: <ul style="list-style-type: none"> firm has submitted new proposed brand name i.e Calvita Pro Syrup. Monograph of iron bisglycinate is required.
109.	Cor-Vit D tablet	Deferred for following reasons: <ul style="list-style-type: none"> firm has submitted new proposed brand name i.e Med-D chewable tablet. Master formula of chewable tablet as dosage form is needed.
110.	Lycovit syrup	Deferred for following reasons: <ul style="list-style-type: none"> firm has submitted new proposed brand name i.e Calvita Pro Syrup. Monograph of calcium lactate gluconate is required.
111.	Mango-C sachet	Deferred for following reasons: <ul style="list-style-type: none"> has submitted new proposed brand name i.e Myo-Med Sachet. Monograph of L-methyl folate is required.
112.	Choarqa tablet	Deferred for following reasons: <ul style="list-style-type: none"> firm has submitted new proposed brand name i.e Mede-Cal tablet. Monograph of vitamin K2 is required.
113.	Olive oil drop	Deferred for further evaluation and clarification.



S.No (1)	Brand name (2)	Decision (3)
114.	Arq-e-Badaniya	Deferred for following reasons: <ul style="list-style-type: none"> • Firm has submitted new proposed brand name i.e Sea-Med tablet. • Monographs of red algae calcium and vitamin K2 are required.
115.	Araq-e- gulab Spray	Deferred for following reasons: <ul style="list-style-type: none"> • firm has submitted new proposed brand name i.e Medeferr tablet. • Firm applied said product in oral liquid form initially and has changed brand name along with dosage form later, needs clarification.
116.	Ginco Plus tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of L methyl folate is required.
117.	Pe-Cal Effervescent Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • firm has submitted new proposed brand name i.e M-Cal 1000 effervescent tablet. • Manufacturing process regarding effervescent tablet is required.
Phytotia Laboratory, Peshawar 27/28-C, Small Industrial Estate, Kohat Road, Peshawar		
118.	Ortho-A Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Clarification is required either zinc oxide is recommended for oral use. • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
119.	Dycacia Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Sodium bicarbonate comes under common molecules list. • Stability of anise oil and cinnamon Bark oil in tablet dosage form is required. • Monograph of powdered ginger extract is required. • Brand name undertaking is required.
120.	V-Plex Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of iron polymaltose and folic acid are required. • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
121.	Cal-Star Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
122.	Zuka-M Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required. • Brand name needs to be changed.
123.	Ab-One Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP.



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Brand name undertaking is required. • Testing method of finished product is required.
124.	Silym Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required. • Silymarin is added in common molecules list.
125.	V-Plex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
126.	Enerton-S Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
127.	Dycalia Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Sodium bicarbonate is added in common molecules list. • Differential fee is not endorsed by concerned division of DRAP.
128.	Ab-One Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Testing method of finished product is required. • Brand name undertaking is required.
129.	Fenertac Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
130.	Phytotia Saarbhat Toshanda Plus	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
131.	Ener-P Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
132.	Plex-Plus Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
133.	Sharbat Podina Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required. • Monograph of ginger extract is required.
134.	Phytocid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Differential fee is not endorsed by concerned division of DRAP. • Brand name undertaking is required.
135.	Phytotia Colic Syrup	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Differential fee is not endorsed by concerned division of DRAP. Brand name undertaking is required. Unit dose strength is required as 20ml given by firm is not rational.
136.	Phytotia Sharbart Joshanda Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Differential fee is not endorsed by concerned division of DRAP. Monograph of ivy leaf extract is required. Brand name undertaking is required.
SOIS Life Sciences, Karachi Plot No. A-84, S.I.T.E, Phase-I, Super Highway, Karachi		
137.	Zeeova Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Monographs of magnesium sulphate, chromium are required. Fee evidence is required.
138.	Fertil-Z Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monographs of tribulus, alpha Lipoic acid, Taurine, pine bark extract and selenium are required. Testing method of finished product is required.
139.	Cubex Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Monographs of ginkgo biloba, phosphorus and chloride are required. Fee evidence is required.
140.	Zeecran Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Sodium bicarbonate comes under common molecules list. Fee evidence is required.
141.	Myo-Vit Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required.
142.	Hm-Folvit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of iron bisglycinate is required. Fee evidence is required.
143.	Infacure Drops	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monographs of all ingredients in extract form are required.
144.	Ironexen Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monograph of iron chelated is required.
Stiflex Pharmaceuticals Wahcantt 33-B, Small Industrial Estate, Bahtar Road, Wah Cantt		
145.	Imune Plus Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of iron polymaltose is required. Justification of use of zinc oxide in oral dosage form is required. Testing method of finished product is required. Brand name needs to be changed.
146.	Fa Plus Syrup	Deferred for further evaluation and clarification.
147.	Rest Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Product contains melatonin, comes under common molecules list.



S.No	Brand name	Decision
(1)	(2)	(3)
148.	Coral Max Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of red algae (calcium) is required.
149.	Coral Max Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Conversion of strength of vitamin D from mg/g to international unit is required.
Wilshire Laboratories Pvt Ltd, Lahore Plot No.5, Farooq Industrial Estate, 20-KM, Ferozepur Road, Lahore		
150.	Beano (Brand Name Changed To Rytal) Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
151.	Geano Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
152.	Gasrel Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
153.	B12 1000Mcg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
154.	Penemia 1000Mcg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
155.	Qubenza 1000Mcg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
156.	Benzim Natural Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
157.	Abdorex Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
158.	Tummy Care Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Differential fee is required.
159.	Senna-Col Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
160.	Docsen Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
161.	C-Rich 500Mg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
162.	C-Rise Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
163.	C-Rose Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
164.	D-Tab Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
165.	Bon-Med Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
166.	D-Lux Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
167.	E-Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
168.	Finergy Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.



S.No	Brand name	Decision
(1)	(2)	(3)
169.	D+C Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
170.	Aktiv-D Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
171.	G-Lite Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
172.	G-Lean Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
173.	G-Trim Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
174.	Laxante Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
175.	Nutralax Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
176.	Ultralax Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
177.	2G Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
178.	Xtrim Tablet	Deferred for following reasons: <ul style="list-style-type: none">• Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier.• Differential fee is required.
179.	Livell Tablet	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
180.	Actiliv Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
181.	Mvg Gold Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
182.	Revamaxv Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
183.	Multi-G Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
184.	New Viogenic Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
185.	Synergize Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
186.	Vitina Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
187.	Cleanze Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
188.	Senacarb Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
189.	Vigforce Tablet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
190.	X-Fire Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
191.	Zamcal D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
192.	Dv-Cal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
193.	Bonost Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
194.	Herbatrim Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
195.	Slender Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
196.	Craneze Capsule	Deferred for further evaluation and clarification.
197.	Urisept Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
198.	Cranuti Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
199.	D-Cap Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
200.	Bon-Med Capsule	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
201.	D-Lux Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
202.	Livimax Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
203.	V.V Plus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
204.	Vimax Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
205.	Colace 100Mg Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
206.	Senna-Col Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
207.	Docsen Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
208.	Enermax Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
209.	E-Plus Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
210.	Finergy Soft Gel	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
211.	Evita 1000Iu Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
212.	Elevita Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
213.	Esteem Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
214.	J-Plus Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
215.	Jointace Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
216.	Jointeze Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
217.	Pregnacare Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
218.	Neo-Care Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
219.	Gestat Soft Gel	Deferred for further evaluation and clarification.
220.	Prizma Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
221.	Domena Soft Gel	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
222.	X-Dame Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
223.	Quvert Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
224.	Nutrigenic Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
225.	Vital-B Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
226.	Vit-Hair Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
227.	Nutri Hair Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
228.	Gro-Hair Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
229.	Zamcal Forte Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
230.	Dv-Cal Forte Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
231.	Bonost Forte Soft Gel	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
232.	Zomega Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
233.	Xtend Life Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
234.	Vitafish Soft Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
235.	Apperize Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
236.	Appemax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
237.	Eatmax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
238.	Abdorex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
239.	Tummy Care Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
240.	Boost Up Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
241.	Ignize Syrup	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
242.	Enzest Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
243.	Urisept Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
244.	Cranuti Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
245.	Urisept Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
246.	Cranuti Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
247.	D-Drop	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
248.	Bon-Med Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
249.	D-Lux Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
250.	De-Flu (Name Changed To Pronto Natural) Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
251.	Flugo Syrup	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
252.	Codral / 4 Flu Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
253.	De-Tuz Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
254.	Novacold Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
255.	Cofnorm Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
256.	D-Flor Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
257.	Florestore Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
258.	Lacoten Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
259.	Bon-Med Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
260.	D-Lux Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
261.	Enermax Sachet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
262.	E-Plus Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
263.	Finergy Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
264.	Exen D Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
265.	D+C Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
266.	Aktiv-D Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
267.	Fiore Natural Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
268.	Ferovina Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
269.	Iron Up Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
270.	Hushh For Adults (Sugar Free) Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
271.	Chestal Syrup	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
272.	Qurex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
273.	Laxante Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
274.	Nutralax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
275.	Ultra-Lax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
276.	Little'S Cold For Children Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
277.	Vanikuf Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
278.	Nocold Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
279.	Liv-Long Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
280.	Livell Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
281.	Actiliv Syrup	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
282.	Mvg Gold Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
283.	Revamax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
284.	Multi-G Syrup	Deferred for further evaluation and clarification.
285.	Revamax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
286.	Multi-G Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
287.	Cepacol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
288.	Zepacol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
289.	Ferogin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
290.	Hemowel Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
291.	Zamcal D Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
292.	Dv-Cal Dry Suspension	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
293.	Bonost Dry Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
294.	Zegut Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
295.	Evora Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
296.	Theralac Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
297.	Crystal Light Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
298.	Vit-Light Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
299.	K-Shot Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
300.	K-Lux Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
301.	K-Max Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
302.	Fastrel Ointment	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
303.	Flexel Ointment	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
304.	Proflex Ointment	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
305.	De-Tuz (Sugar Free) Lozenge Tablet	Deferred for further evaluation and clarification.
306.	Novacold Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
307.	Cofnorm Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
308.	Coldeze Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
309.	Raspeze Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
310.	Smootheze (Sugar Free) Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
311.	Coldeze Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
312.	Raspeze Lozenge Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. • Differential fee is required.
313.	Actigel (Oral) Gel	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
314.	Adora Powder Milk Powder	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
315.	Neo Milk Powder Milk Powder	Deferred for following reasons: <ul style="list-style-type: none"> Dossier is devoid of all requirements laid down in form 3 of SRO 412(I)/2014 except submission of undertaking of contents of dossier. Differential fee is required.
Apple Laboratories, Islamabad National Industrial Zone, RCCI Road, 1.5-KM, Rawat, Rawalpindi		
316.	Aperex Syrup (837)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Form 3 attested and stamped by owner/ CEO is required. Sodium bicarbonate is added in common molecules list.
317.	Hepqure Capsule	Deferred for further evaluation and clarification.
318.	Api-Up Syrup (839)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monographs of foeniculum extract, trigonella foenum-gracum extract and zingiber extract are required. Form 3 attested and stamped by owner/ CEO is required.
319.	Casigeno Cream (840)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Form 3 attested and stamped by owner/ CEO is required. Methyl salicylate is added in common molecules list. Availability of gas chromatography instrument for test/ analysis of turpentine oil is required as mentioned in dossier.
320.	Ava-C Sachet (841)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Form 3 attested and stamped by owner/ CEO is required.
321.	Apsure Adult Milk (842)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Form 3 attested and stamped by owner/ CEO is required. Dextrose is added in common molecules list. Food supplement availability is required. Monograph of skimmed milk powder is required.
Etihad Herbal Industries, Lahore 9.5-KM, Sheikhpura Road, Lahore-Pakistan		
322.	Sharbat Faulad Syrup (843)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monograph of iron compound (folad patri) is required and clarification of its use in health products.
323.	Fresh Bloom Syrup (844)	Deferred for following reasons: <ul style="list-style-type: none"> fee evidence is required. Salt of iron and its monograph are required.



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Brand name needs to be changed.
324.	GinkoBext Syrup	Deferred for further evaluation and clarification.
325.	Arq-E-Mehzal Arq (846)	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Monograph of menthe slyvestris is required. Safety undertaking of product is required. Stability of all ingredients in water (only) as an inactive ingredient is required.
326.	Gluta-D Capsule (847)	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required.
327.	D-Call Supplement (848)	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Monographs of magnesium oxide is required. Unit dose per serving is required. Stability of formulation in powder/ granules is required. Jar filling machine availability is required.
328.	D-Chiro Plus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required.
329.	Myomelat Sachet (850)	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Melatonin is added in common molecules list. Stability of formulation in powder/ granules is required.
330.	Ginbest Syrup (851)	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Citicholine is added in common molecules list. Monograph of ginkgo extract is required.
331.	Link-D (1000IU)	Deferred for further evaluation and clarification.
332.	Elliko Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Monographs of ginseng and ginkgo biloba extract are required.
333.	Elli-D Softgel	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Stability confirmation of vitamin K2 in softgel preparation is required. Monograph of vitamin K2 is required.
334.	Orthorid Super Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required. Glucosamine, chondroitin and hyaluronic acid are added in common molecules list. Monograph of collagen is required and also provide type of collagen which is to be used in formulation. Justification of use of methylene chloride as inactive ingredient is required.
335.	QoloniTaryaq-e-Badan Capsule	Deferred for further evaluation and clarification.
336.	Mactose Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Firm uses herbs in crude form.
337.	Maca Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Breakup of fee is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Monograph of lepidium meyenii is required.
338.	Milk Pro Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Firm uses herbs in crude form.
339.	Amino-Health Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Monographs of L-arginine and L-ornithine are required. • Testing method of finished product is required.
340.	Colic Drop	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Beta galactosidase (lactase) is added in common molecules list. • Drop filling machine availability is required.
341.	Eryon Softgel	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required.
342.	Zippy-D (10000IU) Softgel	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Brand name undertaking is unstrapped and un-signed.
343.	Bi-Digas Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
344.	Bone Fol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required.
345.	Brodil Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Monographs of ivy leaf extract and licorice extract are required.
346.	E-Coline Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required.
347.	Zie-Cid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
348.	Etihad Ghutti Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
349.	Heparax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form. • Brand name needs to be changed.
350.	Ibofen Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required.



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form. • Brand name needs to be changed.
351.	Colic Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
352.	Dyromax Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
353.	Fefivit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Justification of use of methylene chloride as an inactive ingredient is required.
354.	E-Flu Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Firm uses herbs in crude form, needs clarification.
355.	Spongel mouth gel 25gm Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • The product is claimed to be pain relieving. • Oral (gel) section availability is required.
356.	Capsiloc 30gm Gel	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Justification of use of capsicum oleoresin is required.
357.	Fitness Super Tonic Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Clarification is required either said formulation covers under Arq (herbal) or Syrup (nutraceutical) section as firm uses herbs in crude form.
358.	G-Lec Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Firm uses herbs in crude form, needs clarification.
359.	Phaki	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Firm uses herbs in crude form, needs clarification.
360.	Dreamset Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Safety profile of valerian extract is required. • Justification of use of methylene chloride as an inactive ingredient is required.
361.	Power Max Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Firm uses tribulus in crude form, needs clarification.
362.	Protect Capsule	Deferred for further evaluation and clarification.
363.	Glucose-D Plus sachet	Deferred for following reasons:



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Breakup of fee is required. • Glucose is added in common molecules list. • Form 3 is un-stamped and un-signed. • Stability of vitamin D in powder/granules form is required.
364.	Miti Chore Suspension	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Monograph of copper and its salt is required. • Brand name needs to be changed.
365.	Fix Balm	Deferred for following reasons: <ul style="list-style-type: none"> • Breakup of fee is required. • Winter green is added in common molecules list. • Monographs of turpentine oil and menthol are required.
Phytocon International Private Limited, Lahore 339-A, Sundar Industrial Estate, Raiwind Road, Lahore		
366.	Arbucon Cream	Deferred for further evaluation and clarification.
367.	Emolin Cream	Deferred for following reasons: <ul style="list-style-type: none"> • Paraffin is added in schedule D of LRA rules, 1976, needs clarification of its use in health products. • Differential fee is required.
SOIS Life Sciences, Karachi Plot No. A-84, S.I.T.E, Phase-I, Super Highway, Karachi		
368.	Evanol Softgel	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required. • Stability of formulation in softgel dosage form is required.
369.	Caltramag-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required. • Prescribed form 3 to be changed w.r.t addition of salts against each vitamins and minerals.
Opal Laboratories, Karachi Plot LC 42, Lite Landhi, Karachi		
370.	Hb-Booster Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Firm has changed brand name i.e femalt syrup. • Monographs of iron bisglycinate and malt extract are required.
371.	Caripill Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Carica papaya leaf extract monograph is required. • Differential fee is required.
372.	Caripill Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Carica papaya leaf extract monograph is required. • Differential fee is required.
Phytocon International Private Limited, Lahore 339-A, Sundar Industrial Estate, Raiwind Road, Lahore		
373.	Ceramon Lotion	Deferred for following reasons: <ul style="list-style-type: none"> • The product is claimed to be cosmetic. • Differential fee is required. • Hyaluronic acid is added in common molecules list.
Scotmann Pharmaceutical, Islamabad 5-D, I-10/3 Industrial Area, Islamabad		

S.No	Brand name	Decision
(1)	(2)	(3)
374.	Profemme Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of genistein and teavigo are required. • Justification of use of both beta carotene and vitamin in same formulation is required. • 2 tablet per serving dose justification is required.
375.	Probono Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of genistein and magnesium are required. • 2 tablets per serving dose is required.
376.	Obino Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of vitamin B1, vitamin B2, vitamin B3, vitamin B6, zinc and teavigo are required. • 2 tablets per serving dose justification is required. • Testing method of finished product is required. • Prescribed form 3 is required.
377.	Behold Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of vitamin B1, vitamin B2, vitamin B3, vitamin B6, teavigo, hydroxyl tyrosol are required. • Testing method of finished product is required. • Beta carotene exceeds RDA, needs clarification.
378.	Curcuma Softgel	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Stability of turmeric in softgel dosage form is required.
379.	Hitrax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of vitamin B1, vitamin B2, vitamin B3 are required. • 2 tablets per serving dose justification is required.
380.	Brainy Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monographs of vitamin B1, vitamin B6 are required. • Beta carotene exceeds RDA, needs clarification. • Caffeine is added in common molecules list. • Prescribed form 3 is required.
381.	Hartiest Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of vitamin B2, vitamin B6 teavigo are required. • Clarification of use of teavigo is required. • 2 tablets per serving dose justification is required. • Testing method of finished product is required. • Brand name needs to be changed.
382.	Imuna Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monographs of vitamin B1, vitamin B6, vitamin D, zinc, teavigo are required. • Beta carotene exceeds RDA, needs clarification.
383.	Ocupro Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Prescribed form 3 is required. • Monograph of genistein is required.




S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Beta carotene exceeds RDA, needs clarification.
384.	Nutrion Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Prescribed form 3 is required. Monographs of vitamin B1, vitamin B2, vitamin B3, vitamin B6, iodine are required. Clarification is required which type/ kind of vitamin K is used in formulation. 2 tablets per serving dose is required.
Sois Life Sciences, Karachi Plot No. A-84, S.I.T.E, Phase-I, Super Highway, Karachi		
385.	Ocupure Softgel	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monographs of lutein and zeaxanthin are required. Testing method of finished product is required. Stability of formulation in softgel dosage form is required.
386.	Tufcuf Softgel	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monographs of Echinacea, elderberry and white willow are required. Stability of formulation in softgel dosage form is required. Testing method of finished product is required.
Scotmann Pharmaceutical, Islamabad 5-D, I-10/3 Industrial Area, Islamabad		
387.	Emkay Plus Softgel	Deferred for following reasons: <ul style="list-style-type: none"> Prescribed form 3 is required. Monograph of red algae calcium is required.
Alpha Nutraceutical, Lahore 21/S, Quaid-e-Azam, Industrial Estate, Kot Lakhpat, Lahore		
388.	Kufpro Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Differential fee is required. Monographs of banafsha extract, cinamom extract, glychhriza extract and lasoodi extract are required. testing method of finished product is required.
389.	Glosil Plus Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Differential fee is required. Monograph of foeniculum vulgare is required.
390.	Prochel Tablet	Deferred for further evaluation and clarification.
391.	Propol-G Syrup	Deferred for further evaluation and clarification.
392.	Axio Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Differential fee is required. Monographs of ginger extract and fennel extract are required.
393.	Myderm Lotion	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Sulphur is added in common molecules list. Differential fee is required.
394.	Propol-G Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Differential fee is required. Stability of omega 3 fatty acids in tablet dosage form is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Justification of stability and use of zinc oxide in oral dosage form is required. Testing method of finished product is required.
395.	Moringa Capsule	Deferred for further evaluation and clarification.
M/s Phytocon International Private Limited 339-A, Sundar Industrial Estate, Raiwind Road, Lahore		
396.	Hi-Vit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Monographs of vitamin D3, ferrous gluconate, manganese sulphate are required. Justification is required regarding use of zinc oxide in oral dosage form.
Viegen Pharma, Lahore Plot No. 74-G, Sundar Industrial Estate, Sundar Raiwind Road, Lahore		
397.	Pholx Tablet	Deferred for further evaluation and clarification.
398.	Jufex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Monograph of hedera folium extract is required.
399.	LCT Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Justification of use of zinc oxide in oral dosage form is required.
Phytocon International Private Limited, Lahore 339-A, Sundar Industrial Estate, Raiwind Road, Lahore		
400.	Go-Stress Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of withania somnifera extract is required.
401.	Unipep Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Serratiopeptidase is included in common molecules list.
402.	P-Glyce Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of ginger extract is required. Justification is required regarding use of licorice liquid extract in hard shell capsule.
Scotmann Pharmaceutical, Islamabad 5-D, I-10/3 Industrial Area, Islamabad		
403.	Kiddy-D Softgel	Deferred for further evaluation and clarification.
Nutritional Food Works and Chemicals, BWP Plot No.66-67-A, Small Industrial Estate, Bahawalpur		
404.	Calvit-C Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Dextrose is added in common molecules list. Clarification of “ each tube contains” in calvit-C sachet is required, needs correction. Justification of role of anhydrous citric acid as an active ingredient is required.
Huzaifa International, Sargodha Commerical Area, Aziz Bhatti Town Sargodha M/s SUPER’S DIANA, S.L., ubicada a Ctra. C-17, KM 17, del municipi de Parets del Valles, (Barcelona)		
405.	Eli-Plus Liquid (veterinary)	Deferred for following reasons: <ul style="list-style-type: none"> Form 5 is un-stamped. Photocopy of Free sale certificate is attached. Original FSC notarized by law representative and countersigned by Pakistan embassy/ consulate in country of origin, is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> According to real time and accelerated stability data of required batches, range of assay results of vitamin E is from 95.45g/L to 93.24g/L at 18 months' time point to 36 months' time points, clarification/ justification is required either assay of vitamin E at above mentioned time points falls within specified limit or otherwise. CoA of finished product is required. Contents undertaking is required. Manufacturing license is required. Last inspection report is required.
M/s. Agro Poul Vet International, 1/12-A, Sheet No. 24, Model Colony, Karachi Agent of M/s Inner Mongolia Huatian Pharmaceutical Co., Ltd. Economic Development zone, Yuanhbaoshan District, ChiFeng city, Inner Mongolia, P.R. CHINA		
406.	Vitamino Plus Feed Supplement Liquid Solution	Deferred for further evaluation and clarification.
Nutrimed Laboratories, Karachi Plot No. B-42, S.I.T.E. Super Highway, Karachi		
407.	Geri Phos Syrup	Deferred for further evaluation and clarification.
Calgan Phyto Pharma Pvt Ltd, Plot No. 2, Green Park Road, Near Band Road Grid Station, Lahore		
408.	Algium Tablet	Deferred for further evaluation and clarification.
409.	Vitamix Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required.
410.	Gyne-5 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Strength of ingredients is required.
411.	Martacid Liquid	Deferred for further evaluation and clarification.
412.	Calpan-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of vitamin K2 is required. Monograph of algae mineral complex is required.
413.	Oscal Insta Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Stability of vitamin D3 in powder/ granules dosage form is required.
414.	Fosgink Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required. Form 3 to be revised w.r.t omission of sorbitol as it is an inactive ingredient.
Nutrimed Laboratories, Karachi Plot No. B-42, S.I.T.E. Super Highway, Karachi Evaluator: (Zain Ul Abidin, AD-V)		
415.	Refort-M Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Unit dose strength is required. Monograph of fish oil is required. Brand name undertaking is required.
416.	Renobex-M Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Unit dose strength is required.
Phytocon International Private Limited, Lahore 339-A, Sundar Industrial Estate, Raiwind Road, Lahore		
417.	Enzilact Drops	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none">• Differential fee is required.• Lactase is added in common molecules list.
PolyfineNutra-Sciences Plot No. 39-40 D, Industrial Estate, Hayatabad, Peshawar		
418.	Calrex-D Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.• Formulation contains large amount of calcium carbonate i.e 12gm in 120ml, needs justification.
419.	Vitora-D Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.• Strength of ingredients are required.
420.	Cytaplex Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.
421.	Incomin Syrup	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.
422.	Vitazee Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Unit dose strength is required.• Fee evidence is required.
423.	Iron-F Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.
424.	Zybex-L Liquid	Deferred for following reasons: <ul style="list-style-type: none">• Fee evidence is required.


(Muhammad Abdul Ghaffar)
Secretary, EEC

